Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zadaxin + DTIC + IFN in Metastatic Melanoma
NCT00911443Phase 2Completed
- Sponsor
- Sigma-Tau
- Start
- Jul 2002
- Primary completion
- Sep 2007
- Modality
- Peptides
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of thymosin alpha 1 in Malignant Melanoma (MM) (5 arms), sponsored by Sigma-Tau. Primary endpoint: Overall Tumor Response at 1 year. Started Jul 2002; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00911443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00911443.